Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 3/20 | 0.56 |
| ▸ | FLT1 | P17948 | 3/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979887 | 0.88 | KDR (0.67) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3977506 | 0.87 | KDR (0.59) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3977937 | 0.84 | RET (0.56) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3978118 | 0.82 | KDR (0.55) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3980106 | 0.81 | KDR (0.66) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3986474 | 0.81 | KDR (0.54) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3979524 | 0.79 | KDR (0.56) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL4489347 | 0.79 | KDR (0.57) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL3982890 | 0.77 | KDR (0.50) | KDRFGFR1RETFLT1MAP4K4 | |
| SCHEMBL14013968 | 0.74 | FGFR1 (1.00) | KDRFGFR1RETFLT1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566721-B2 | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | claimed |
| EP-2051982-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2008018881-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | claimed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | claimed |
| US-7566721-B2 | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-2051982-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008018881-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018881-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | IGF1R, BRCA1, MAP2K6 | KDR 2130/4885FGFR1 64/4885RET 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.